Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?
Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases investor.omeros.com. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rights investor.omeros.com reuters.com. Reuters reports that Omeros stock “more than doubled to $9.90” in early trading after the news reuters.com, and by market close had settled near $10.10 investing.com. TechStock² (ts2.tech) notes Omeros shares surged roughly 65% on the announcement ts2.tech. The deal is structured as an